Oculis Holding AG announced presentations showcasing Privosegtor, a novel drug candidate with neuroprotective potential for optic neuritis, supported by positive Phase 2 ACUITY trial results. The drug improved visual function and preserved retinal anatomy, earning Breakthrough Therapy and PRIME designations from US and European regulators. Oculis is advancing Privosegtor in the PIONEER registrational program and expects to begin trials for acute multiple sclerosis relapses in late 2026. Upcoming presentations at APOIS Congress and CNS Summit will detail these findings.
Oculis Holding AG's neuroprotective drug candidate Privosegtor is featured in upcoming presentations, providing context for readers following health-sector developments. For readers following health-sector US stocks on Pluang, here is the market snapshot as of Oct 29, 2026 14:11 WIB: out of 150 priced stocks, 105 rose and 42 fell. Notable movers include RGEN at USD 183.48 with a 4.37% increase and a typical hold time of 4 days, CRL at USD 373.98 up 4.22% with a 34-day hold time, and INO at USD 0.96 rising 3.92%, with Pluang order activity showing 65% sell and 35% buy, and a typical hold time of 43 days.
Wolters Kluwer repurchased 479 of its own shares between October 22 and October 28, 2026, spending €0.04 million at an average price of €85.98 per share. This buyback is part of a larger €500 million program announced earlier in 2026, with a total of...
IPQualityScore (IPQS) advises banks, fintechs, and merchants to enhance fraud prevention by assessing account, device, and connection risks alongside AI-agent authorization. Their proprietary network of over 100,000 honeypots worldwide gathers firsth...
Philips has introduced UniGuide 3D Live Guidance, a new CE-marked solution that integrates CT-derived planning insights directly into live procedures using its Azurion image-guided therapy platform. This technology allows physicians to access detaile...
DNO ASA, a Norwegian oil and gas company, announced a cash dividend of NOK 0.375 per share to be paid around November 17, 2026. Shareholders registered by November 9, 2026, will receive the dividend, with shares trading ex-dividend starting November ...
TGS ASA announced that its shares will be traded ex-dividend at NOK 1.45 per share starting October 29, 2026. This means investors buying the stock from this date will not receive the upcoming dividend payment. The dividend distribution follows appro...
